Literature DB >> 7577027

The effect of blood transfusions on survival after surgery for colorectal cancer.

O R Busch1, W C Hop, R L Marquet, J Jeekel.   

Abstract

The immunosuppressive effect of allogeneic blood transfusions can be associated with a poor prognosis for cancer patients. Predeposit autologous blood transfusions could be a solution to overcome this putative deleterious effect. We performed a randomised clinical study to compare the effects of autologous with allogeneic blood transfusions in colorectal cancer patients. There was no significant difference in disease-free survival between both randomisation arms. However, the transfused patients had a significantly shorter disease-free interval as compared with the non-transfused patients. This association of transfusions with recurrent disease was only the case for local recurrences, whereas the incidence of distant metastases was unaffected. We conclude that the use of a predeposit autologous blood transfusion programme does not improve the prognosis in colorectal cancer patients. The negative association between blood transfusions and cancer recurrence is only true for local recurrences, which suggests that not the blood transfusions themselves but rather the circumstances necessitating them are the real predictors of prognosis.

Entities:  

Mesh:

Year:  1995        PMID: 7577027     DOI: 10.1016/0959-8049(95)00174-h

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Perioperative allogenic blood transfusion and serum levels of immunosuppressive acidic protein in patients undergoing resection of colorectal carcinoma.

Authors:  T Iwanaga; H Suzuki
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

2.  Blood transfusion does not adversely affect survival after elective colon cancer resection: a propensity score analysis.

Authors:  Ignazio Tarantino; Kristjan Ukegjini; Rene Warschkow; Bruno M Schmied; Thomas Steffen; Alexis Ulrich; Sascha A Müller
Journal:  Langenbecks Arch Surg       Date:  2013-07-11       Impact factor: 3.445

3.  Predictors of blood transfusion requirement in elective liver resection.

Authors:  Andrew J Cockbain; Tahir Masudi; J Peter A Lodge; Giles J Toogood; K Raj Prasad
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

Review 4.  Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions.

Authors:  J P Cata; H Wang; V Gottumukkala; J Reuben; D I Sessler
Journal:  Br J Anaesth       Date:  2013-05       Impact factor: 9.166

Review 5.  Perioperative blood transfusions for the recurrence of colorectal cancer.

Authors:  A Amato; M Pescatori
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

6.  Perioperative blood transfusion as a poor prognostic factor after aggressive surgical resection for hilar cholangiocarcinoma.

Authors:  Norihisa Kimura; Yoshikazu Toyoki; Keinosuke Ishido; Daisuke Kudo; Yuta Yakoshi; Shinji Tsutsumi; Takuya Miura; Taiichi Wakiya; Kenichi Hakamada
Journal:  J Gastrointest Surg       Date:  2015-01-21       Impact factor: 3.452

Review 7.  The Effect of Anesthesia on the Immune System in Colorectal Cancer Patients.

Authors:  Yangjie Dang; Xingxing Shi; William Xu; Mingzhang Zuo
Journal:  Can J Gastroenterol Hepatol       Date:  2018-04-01

Review 8.  Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion.

Authors:  D A Henry; P A Carless; A J Moxey; D O'Connell; M A Forgie; P S Wells; D Fergusson
Journal:  Cochrane Database Syst Rev       Date:  2002

9.  Perioperative Blood Transfusions Are Associated With Worse Overall Survival But Not Disease-Free Survival After Curative Rectal Cancer Resection: A Propensity Score-Matched Analysis.

Authors:  David N Hanna; Adriana C Gamboa; Glen C Balch; Scott E Regenbogen; Jennifer Holder-Murray; Sherif R Z Abdel-Misih; Matthew L Silviera; Michael P Feng; Thomas G Stewart; Li Wang; Alexander T Hawkins
Journal:  Dis Colon Rectum       Date:  2021-08-01       Impact factor: 4.412

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.